Dr. Danong Chen, Chief Executive Officer
Dr. Danong Chen is a seasoned executive with over two decades of experience in corporate strategy and product development and commercialization. She was President and Chief Executive Officer of Tanox, Inc., a Houston based, publicly traded biotherapeutic company, which was one of the largest biotech companies in Texas. During her tenure as the CEO and President, Tanox was acquired by Genentech in 2007 in a transaction valued at about $1 billion. Prior to being named President and CEO, she was Vice President of Strategy and Corporate Development at Tanox, responsible for guiding company strategy, evaluating new product opportunities and potential merger and acquisition transactions, and overseeing annual product prioritization and related budgeting process. Dr. Chen joined Tanox as Associate Director of Strategy in 2002 and between 2002 and 2005 she held increasing responsibilities in areas of Strategy, Corporate and Business Development and Project Management. From April 2008 to Aug 2009, Dr. Chen served as President and Chief Executive Officer of Theranostics Health, Inc., a biotech company focused on developing products for personalized treatments. Prior to joining Tanox, Dr. Chen served as a manager in the health-care practice of Arthur D. Little, Inc., the world’s first strategic consulting company with a reputation and emphasis on innovation and technology based/guided strategies. Early in her career, she developed immunoassay-based clinical diagnostics in Shanghai, China and won a bronze medal from the Chinese government for one of the products she developed. As a trained molecular neuroscientist, she has a deep understanding of molecular and cellular interactions as they relate to drug targets and drug candidates in therapeutic product development. Dr. Chen received her Ph.D. in Neuroscience from Baylor College of Medicine in Houston, TX and MBA from Arthur D. Little School of Management in Boston, MA.
Dr. Glenn Rice, President
Glenn Rice, Ph.D. has been involved with the start up and building of seven biotech companies as founder/ member of the early executive management team, which has led to significant shareholder returns via two reverse IPO’s, two acquisitions and one IPO. Before serving as Director and President of MetronomX, Dr. Rice was COO, President and Director of Pharmacyclics, Inc. a NASDAQ listed drug company with four drugs in the clinic for cancer, autoimmune and allergic diseases. During his tenure he raised $30M in public equity and the stock price increased 500%. Dr. Rice continues to sit on the Board of Directors for Pharmacyclics. He is founder and former CEO of two China-focused companies, Pacific Biopharma Group, Ltd. (Taizhou), and Bridge Laboratories, Ltd. (Beijing), which he built to 300 employees and significant revenues. Dr. Rice was the former head of life sciences at SRI International directing over 160 staff, and was the former VP of Research and Board Director of NASDAQ listed ILEX Oncology, which was later sold to Genzyme Corp. in 2004 for $1 billion. Prior to ILEX he was a founder and CEO of Convergence Pharmaceuticals, Inc., a Boston-based oncology company; a founder and Director of EmergingMed, an online clinical trial prequalification company; and a past Director and co-founder of C-PATH Institute, a non-profit Institute that is focused on drug development and regulatory innovation. Dr. Rice began his career as a laboratory director at Genentech, and is an inventor on over 20 patents or patent applications, authored over 75 manuscripts and book chapters, and has had extensive experience raising substantial private and public equity and corporate partnerships.
Dr. Michael Adams, Consulting Manufacturing Advisor
Michael Adams has 25 years of experience in drug development. He currently works as consultant/advisor to Pharmaceutical and biotech companies in CMC development and drug regulatory affairs. Previously, he was SVP of Pharmaceutical Operations at Spectrum Pharmaceuticals, Inc. He is also an Entrepreneur‐in‐residence at CONNECT helping pharma/biotect start up companies. Before joining Spectrum, Michael was Senior Vice President, Drug Development Operations at Anadys Pharmaceuticals, Inc. Michael had responsibility for regulatory affairs, quality assurance, pharmaceutical development and manufacturing, and project management. Previous to Anadys, Michael had been Vice President, Pharmaceutical Sciences at Pfizer, Inc. ‐‐ Global Research & Development in La Jolla, CA since 2000. At Pfizer he led the La Jolla organization responsible for chemical, analytical and pharmaceutical development from compound identification through launch and product enhancement. Previously, he was Vice President, Worldwide Regulatory Affairs, and Quality Assurance & Compliance at Agouron Pharmaceuticals, also in La Jolla, where he put together the firm's Regulatory CMC group. Prior to Agouron, he was the Director of Worldwide Regulatory Affairs, CMC Group, at Bristol‐Myers Squibb, where he managed Regulatory CMC projects in CNS and CV/MD therapeutic areas. Michael earned a Ph.D. in Organic Chemistry at the Massachusetts Institute of Technology in Cambridge, MA.